These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10404432)

  • 21. The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases.
    Dezso B; Haas GP; Hamzavi F; Kim S; Montecillo EJ; Benson PD; Pontes JE; Maughan RL; Hillman GG
    Clin Cancer Res; 1996 Sep; 2(9):1543-52. PubMed ID: 9816331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.
    Tian H; Shi G; Yang G; Zhang J; Li Y; Du T; Wang J; Xu F; Cheng L; Zhang X; Dai L; Chen X; Zhang S; Yang Y; Yu D; Wei Y; Deng H
    BMC Cancer; 2014 Jan; 14():48. PubMed ID: 24475975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A; Aruga E; Cameron MJ; Chang AE
    J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
    Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
    J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines.
    el-Shami KM; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    J Interferon Cytokine Res; 1999 Dec; 19(12):1391-401. PubMed ID: 10638708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of GM-CSF signaling in cell-based tumor immunization.
    Zarei S; Schwenter F; Luy P; Aurrand-Lions M; Morel P; Kopf M; Dranoff G; Mach N
    Blood; 2009 Jun; 113(26):6658-68. PubMed ID: 19282460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Application of a tumor cell vaccine transfected with GM-CSF/IL-2 fusion gene for specific immunotherapy of hepatocellular carcinoma].
    Guo C; Liu QG; Yang W; Yao YM
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):188-92. PubMed ID: 18250039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.
    Shorts L; Weiss JM; Lee JK; Welniak LA; Subleski J; Back T; Murphy WJ; Wiltrout RH
    J Immunol; 2006 Jun; 176(11):6543-52. PubMed ID: 16709811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model.
    Lumniczky K; Desaknai S; Mangel L; Szende B; Hamada H; Hidvegi EJ; Safrany G
    Cancer Gene Ther; 2002 Jan; 9(1):44-52. PubMed ID: 11916244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma.
    Ho MY; Sun GH; Leu SJ; Ka SM; Tang SJ; Sun KH
    Int J Cancer; 2008 Jul; 123(1):123-33. PubMed ID: 18386791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The anti-tumor activity of GM-CSF-modified lung cancer cell vaccine and its synergism in combination with chemotherapy].
    Jiang HJ; Ren XB; Li H; Yu JP; Wei F; Ma MQ
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):808-12. PubMed ID: 18396635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma.
    Dybal EJ; Haas GP; Maughan RL; Sud S; Pontes JE; Hillman GG
    J Urol; 1992 Oct; 148(4):1331-7. PubMed ID: 1404669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.
    Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F
    Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
    Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
    Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation.
    Krup OC; Kroll I; Böse G; Falkenberg FW
    J Immunother; 1999 Nov; 22(6):525-38. PubMed ID: 10570751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.